In vivo antibody testing is required to evaluate the therapeutic potential of monoclonal antibodies (mAbs) and other biologics. Unlike in vitro models, which primarily offer insights into molecular interactions, in vivo studies provide essential data on an antibody's pharmacodynamics, pharmacokinetics, and overall safety profile within the complexity of living organisms.
The preclinical testing phase helps answer essential questions about an antibody's mechanism of action, including its ability to engage the immune system effectively or neutralize specific targets under physiological conditions.
These studies also assess safety and tolerability by identifying potential off-target effects, immunogenicity, and toxicity risks. Early detection of these issues ensures that only the most promising candidates proceed to clinical evaluation, reducing costly late-stage failures.
Related: Research-Use-Only (RUO) Biologics for Antibody In Vivo Research
Tools and Models for In Vivo Testing
Choosing the right in vivo model is fundamental to obtaining relevant and translatable results. Common models include rodent systems, such as mouse or rat models, which are well-suited for studying humanized antibodies and immune responses. Transgenic and knockout models further enhance the ability to study specific targets and pathways relevant to human diseases.
Regulatory Expectations
Regulatory agencies, such as the FDA and EMA, require rigorous preclinical testing to ensure the safety of antibodies before human trials. The data generated must demonstrate not only efficacy but also acceptable safety margins, including detailed toxicology reports and immune response profiles.
Adherence to Good Laboratory Practice (GLP) guidelines is essential for ensuring reproducibility and compliance. Regulatory submissions rely heavily on robust, validated in vivo data to support Investigational New Drug (IND) applications.
Biointron’s catalog products for in vivo research can be found at Abinvivo, where we have a wide range of Benchmark Positive Antibodies, Isotype Negative Antibodies, Anti-Mouse Antibodies, Bispecific Antibodies, and Antibody-Drug Conjugates. Contact us to find out more at info@biointron.com or +86 400-828-8830 / +1(732)790-8340.
DOI: 10.3389/fbioe.2022.856049Antibodies have become essential tools for the diagnosis and treatment of numerous human diseases. However, non-human antibodies, such as those derived from murine sources, often provoke human anti-mouse antibody (HAMA) responses. This immunogenicity leads to rapid clea
In therapeutic antibody development, achieving high-affinity antigen binding is central to improving drug efficacy, durability, and safety.Biointron’s High-Throughput Fully Human Antibody Discovery service is designed to meet this need by integrating advanced screening and engineering technol
I. Introduction to Hybridoma TechnologyHybridoma technology, developed by Köhler and Milstein in 1975, is a foundational method for producing monoclonal antibodies (mAbs). The approach involves fusing antibody-producing B lymphocytes with immortal myeloma cells to form hybridoma cells. These hybrid
Introduction to Monoclonal Antibody Discovery Monoclonal antibodies (mAbs) are one of the most successful classes of biologic drugs on the global pharmaceutical market. Since the approval of Orthoclone OKT3 in 1986, over 100 mAbs have been approved by the U.S. FDA for indications incl
ScientistとScience Exchangeとのご利用可能です。
